This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101. (December 2022)
Record Type:
Journal Article
Title:
LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101. (December 2022)
Main Title:
LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101